A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT-birch pollen extract for the treatment of allergic rhinitis: results of a phase II study

Background Sublingual immunotherapy (SLIT) is a potential efficacious and safe treatment option for patients with respiratory, IgE-mediated allergic diseases. A combined tolerability, dose-finding study with a sublingual liquid birch pollen preparation (SB) was conducted. Methods Two hundred and six...

Full description

Saved in:
Bibliographic Details
Main Author: Pfaar, Oliver (Author)
Format: Article (Journal)
Language:English
Published: January 2016
In: Allergy
Year: 2016, Volume: 71, Issue: 1, Pages: 99-107
ISSN:1398-9995
DOI:10.1111/all.12760
Online Access:Verlag, Volltext: http://dx.doi.org/10.1111/all.12760
Verlag, Volltext: https://onlinelibrary-wiley-com.ezproxy.medma.uni-heidelberg.de/doi/abs/10.1111/all.12760
Get full text
Author Notes:O. Pfaar, E. van Twuijver, J.D. Boot, D.J.E. Opstelten, L. Klimek, R. van Ree, Z. Diamant, P. Kuna, P. Panzner

MARC

LEADER 00000caa a2200000 c 4500
001 1586308483
003 DE-627
005 20230427034205.0
007 cr uuu---uuuuu
008 190116s2016 xx |||||o 00| ||eng c
024 7 |a 10.1111/all.12760  |2 doi 
035 |a (DE-627)1586308483 
035 |a (DE-576)516308483 
035 |a (DE-599)BSZ516308483 
035 |a (OCoLC)1341033615 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Pfaar, Oliver  |d 1972-  |e VerfasserIn  |0 (DE-588)12385900X  |0 (DE-627)706454049  |0 (DE-576)293913099  |4 aut 
245 1 2 |a A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT-birch pollen extract for the treatment of allergic rhinitis  |b results of a phase II study  |c O. Pfaar, E. van Twuijver, J.D. Boot, D.J.E. Opstelten, L. Klimek, R. van Ree, Z. Diamant, P. Kuna, P. Panzner 
264 1 |c January 2016 
300 |a 9 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 16.01.2019 
520 |a Background Sublingual immunotherapy (SLIT) is a potential efficacious and safe treatment option for patients with respiratory, IgE-mediated allergic diseases. A combined tolerability, dose-finding study with a sublingual liquid birch pollen preparation (SB) was conducted. Methods Two hundred and sixty-nine adults with birch-pollen-induced AR were randomized to placebo, SB: 3333, 10 000, 20 000 or 40 000 AUN/ml. Differences in symptom scores following a titrated nasal provocation test (TNPT) at baseline and after 5 months of treatment were determined. Safety, tolerability, birch-pollen-specific immunoglobulin levels and peak nasal inspiratory flow (PNIF) were also measured (all measures determined outside the birch pollen season). Results In all treatment groups, an improvement in symptom scores after treatment compared to baseline was observed, with an additional stepwise improvement in the active groups compared to placebo, which was significant in high-dose groups (P = 0.008 and P < 0.001, respectively). For this primary endpoint, a significant linear dose-response curve was observed: the higher the dose, the better the improvement observed. Likewise, active treatment resulted in an increase in PNIF and serum IgG levels compared to placebo. The highest improvements were found in the 40 000 AUN/ml group. All active dosages resulted in more adverse reactions than placebo, which were mainly mild and well-controlled. Conclusions A multicentre trial evaluated the dose-response and tolerability of SB. All active treatment groups showed better responses than placebo for both primary and secondary parameters. The results indicate that, within the studied dose range, SB 40 000 AUN/ml is the most optimal effective and safe dose (ClinicalTrials.gov: NCT01639768). 
650 4 |a allergen immunotherapy 
650 4 |a birch pollen 
650 4 |a dose finding 
650 4 |a nasal provocation 
650 4 |a sublingual immunotherapy 
773 0 8 |i Enthalten in  |t Allergy  |d Oxford : Wiley, 1978  |g 71(2016), 1, Seite 99-107  |h Online-Ressource  |w (DE-627)320425428  |w (DE-600)2003114-2  |w (DE-576)091140153  |x 1398-9995  |7 nnas  |a A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT-birch pollen extract for the treatment of allergic rhinitis results of a phase II study 
773 1 8 |g volume:71  |g year:2016  |g number:1  |g pages:99-107  |g extent:9  |a A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT-birch pollen extract for the treatment of allergic rhinitis results of a phase II study 
856 4 0 |u http://dx.doi.org/10.1111/all.12760  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://onlinelibrary-wiley-com.ezproxy.medma.uni-heidelberg.de/doi/abs/10.1111/all.12760  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20190116 
993 |a Article 
994 |a 2016 
998 |g 12385900X  |a Pfaar, Oliver  |m 12385900X:Pfaar, Oliver  |d 60000  |d 62100  |e 60000PP12385900X  |e 62100PP12385900X  |k 0/60000/  |k 1/60000/62100/  |p 1  |x j 
999 |a KXP-PPN1586308483  |e 3045885136 
BIB |a Y 
SER |a journal 
JSO |a {"relHost":[{"origin":[{"dateIssuedKey":"1978","publisherPlace":"Oxford ; Oxford","publisher":"Wiley ; Blackwell Munksgaard","dateIssuedDisp":"1978-"}],"title":[{"title_sort":"Allergy","title":"Allergy"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["320425428"],"zdb":["2003114-2"],"issn":["1398-9995"],"doi":["10.1111/(ISSN)1398-9995"]},"part":{"issue":"1","extent":"9","text":"71(2016), 1, Seite 99-107","volume":"71","pages":"99-107","year":"2016"},"note":["Gesehen am 14.08.14"],"recId":"320425428","disp":"A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT-birch pollen extract for the treatment of allergic rhinitis results of a phase II studyAllergy","language":["eng"],"pubHistory":["33.1978 -"],"type":{"bibl":"periodical","media":"Online-Ressource"}}],"note":["Gesehen am 16.01.2019"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"eki":["1586308483"],"doi":["10.1111/all.12760"]},"physDesc":[{"extent":"9 S."}],"language":["eng"],"title":[{"subtitle":"results of a phase II study","title_sort":"randomized DBPC trial to determine the optimal effective and safe dose of a SLIT-birch pollen extract for the treatment of allergic rhinitis","title":"A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT-birch pollen extract for the treatment of allergic rhinitis"}],"recId":"1586308483","name":{"displayForm":["O. Pfaar, E. van Twuijver, J.D. Boot, D.J.E. Opstelten, L. Klimek, R. van Ree, Z. Diamant, P. Kuna, P. Panzner"]},"origin":[{"dateIssuedKey":"2016","dateIssuedDisp":"January 2016"}],"person":[{"role":"aut","family":"Pfaar","display":"Pfaar, Oliver","given":"Oliver"}]} 
SRT |a PFAAROLIVERANDOMIZED2016